ChemioCare Initiates Development Program in Pediatric CINV NEW YORK, Jan. 04, 2019 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a platform company focused on proprietary transdermal delivery today announced that its Adult...

ChemioCare Expands Proprietary Transdermal Platform DEA Registration granted: expands capability to develop controlled substances via transdermal patches NEW YORK, Oct. 18, 2018 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the...

ChemioCare Announces Addition of Three Experienced Team Members NEW YORK, July 30, 2018 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotech company focused on transforming chemotherapy induced nausea and vomiting (CINV) outcomes...

ChemioCare Announces Addition of Chief Medical Advisor and Director NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotech company focused on transforming chemotherapy induced nausea and vomiting (CINV) outcomes...

ChemioCare Formed to Transform Chemo-Induced Emesis Outcomes Through Patch Technology NEW YORK, March 06, 2018 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare”) today announced it will be leveraging novel transdermal patch technology for the treatment of chemotherapy-induced...